

> Return address PO Box 320, 1110 AH Diemen

To the Minister of Health, Welfare and Sport
PO Box 20350
2500 EJ THE HAGUE

2023007591

Date 22 February 2023
Subject GVS advice lasmiditan (Rayvow®)

**National Health Care
Institute**

Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl

T +31 (0)20 797 85 55

Contact

K. Watson
T +31642024315

Our reference
2023007591

Dear Mr Kuipers,

In your letter of 2 January 2023 (CIBG-23-04902), you asked the National Health Care Institute to assess whether the medicinal product lasmiditan (Rayvow®) can be included in the Medicine Reimbursement System (GVS). You have asked us to deal with this request by means of a marginal review. The National Health Care Institute has completed this substantive assessment. The outcome of this can be found in the enclosed GVS report.

Rayvow® is available as a film-coated tablet with 50 or 100 mg of lasmiditan. It is registered for acute treatment of the headache phase of migraine attacks (with or without aura) in adults.

The recommended starting dose for the acute treatment of adult migraine attacks is 100 mg of lasmiditan. If necessary, the dosage can be increased to 200 mg for greater efficacy or reduced to 50 mg for better tolerability.

According to the marketing authorisation holder, lasmiditan (Rayvow®) is interchangeable with triptans, and can therefore be placed on List 1A of the Health Insurance Regulation (Rzv).

The outcome of the assessment

Based on the criteria for mutual interchangeability, the National Health Care Institute concluded that lasmiditan (Rayvow®) is interchangeable with the seven triptans in the existing GVS cluster ON02CCAO V: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan. The World Health Organization (WHO) has not established a DDD for lasmiditan. The marketing authorisation holder proposes a standard dose of 100 mg per day. The Rayvow® SmPC mentions a recommended starting dose for acute migraine attacks of 100 mg lasmiditan. The standard dose of lasmiditan can be determined accordingly.

Advice

The National Health Care Institute advises you to include lasmiditan (Rayvow®) on List 1A in cluster 0N02CCAO V. The standard dose can be set at 100 mg per attack.

Yours sincerely,

Sjaak Wijma
Chairperson of the Executive Board

**National Health Care
Institute**

Date
22 February 2023

Our reference
2023007591